Current clinical studies have confirmed that donafenib has achieved better results in the first-line treatment of advanced hepatocellular liver cancer, and compared with the targeted drug sorafenib, it can significantly prolong the overall survival time of patients. Donafinil is a multi-target kinase inhibitor drug, which is an oral small molecule targeted drug, playing multiple inhibitory roles by inhibiting multiple aspects such as cancer cell proliferation and growth and tumor neovascularization, so as to play a therapeutic purpose of controlling the development of liver cancer lesions. As an antitumor drug, side effects such as hand-foot syndrome, hypertension, diarrhea, liver damage, leukocyte reduction, proteinuria, etc. often occur after its use, so its clinical use must be guided by a professional doctor, and do not use the drug blindly, so as to avoid delaying the condition.